Document is current
Any future updates will be listed below
-
Authors
Cwynarski, Kate https://orcid.org/0000-0001-9936-3431
Iacoboni, Gloria
Tholouli, Eleni
Menne, Tobias
Irvine, David A.
Balasubramaniam, Nivetha
Wood, Leigh
Shang, Justin
Xue, Eric
Zhang, Yiyun
Basilico, Silvia
Neves, Margarida
Raymond, Meera
Scott, Ian
El-Kholy, Mohamed
Jha, Ram
Dainton-Smith, Heather
Hussain, Rehan
Day, William
Ferrari, Mathieu https://orcid.org/0000-0001-8535-7348
Thomas, Simon
Lilova, Koki
Brugger, Wolfram
Marafioti, Teresa
Lao-Sirieix, Pierre
Maciocia, Paul https://orcid.org/0000-0002-9757-8073
Pule, Martin https://orcid.org/0000-0002-8347-9867
- License Information
-
More Information
Article History
Received: 18 January 2024
Accepted: 30 September 2024
First Online: 11 November 2024
Competing interests
: K.C.: consulting/advisory role: Roche, Takeda, Celgene, Atara, Gilead, KITE, Janssen, Incyte and AbbVie; speakers’ bureau: Roche, Takeda, KITE, Gilead and Incyte; conferences/travel support: Roche, Takeda, KITE, Janssen and BMS. G.I.: honoraria and travel support: Novartis, Kite/Gilead, Bristol Myers Squibb, AbbVie, Autolus, Sandoz, Miltenyi and AstraZeneca. E.T.: speaker fees: Astellas, Jazz, Kite/Gilead, Pfizer and Vertex; ad boards: Autolus, BMS/Celgene, Jazz, Janssen and Vertex. M.P.: owns stock in and has research funding and salary contribution from Autolus. D.I.: travel grants and honoraria: Kite/Gilead and Janssen. T.M.: travel grants: Amgen, Jazz, Pfizer, Bayer, Kyowa Kirin, Celgene/BMS, Kite/Gilead, Janssen and Takeda; honoraria for advisory board meetings: Kite/Gilead, Amgen, Novartis, Pfizer, Celgene/BMS, Daiichi Sankyo, Atara, Roche and Janssen; honoraria for lectures: Kite/Gilead, Takeda, Janssen, Roche, Servier, Novartis, Celgene/BMS, Pfizer and Incyte; research funding: Janssen, AstraZeneca and Novartis. T.M.: consulting/advisory role: Roche/Ventana, Haematogenix and Autolus. P.M.: Autolus: stock holder and research funding. UCL business: patent royalties. All employees of Autolus have no competing interests.
